SAB4200010

Anti-Leupaxin (N-terminal) antibody produced in rabbit

affinity isolated antibody, buffered aqueous solution

• Synonym(s): Anti-LDPL, Anti-LPXN
• UNSPSC Code: 12352203
• NACRES: NA.41

Properties

• biological source: rabbit
• conjugate: unconjugated
• antibody form: affinity isolated antibody
• antibody product type: primary antibodies
• clone: polyclonal
• form: buffered aqueous solution
• mol wt: antigen ~43 kDa
• species reactivity: human
• enhanced validation: recombinant expression; Learn more about Antibody Enhanced Validation
• technique(s): western blot: 1-2 μg/mL using extracts of Raji cells
• UniProt accession no.: O60711
• shipped in: dry ice
• storage temp.: −20°C
• target post-translational modification: unmodified
• Gene Information: human ... LPXN(9404)

Description

General description

Leupaxin gene is mapped to human chromosome 11q12.1. Leupaxin belongs to the paxillin protein family It is mainly expressed in macrophages, lymphoid tissues and hematopoietic cells. Leupaxin comprises two types of protein interaction domains, LIM domain and leucine−aspartate (LD) motifs. LIM domains mediate localization to focal contacts. LD motifs facilitates focal adhesion kinase (FAK) and vinculin binding, resulting in the localization of focal adhesion kinase (FAK) to focal adhesions. The C-terminal LIM domains in leupaxin share 70% amino acid identity with paxillin. The N-terminal region of leupaxin comprises three short stretches of 13 amino acids that share 70− 90% similarity with paxillin LD motifs.

Specificity

Anti-Leupaxin (N-terminal) specifically recognizes human leupaxin.

Application

Anti-Leupaxin antibody produced in rabbit has been used in immunoblotting and proximity ligation assay.

Biochem/physiol Actions

Leupaxin in association with a second focal adhesion kinase (FAK) family member, PYK2, acts a cell type-specific signaling complex regulator in leukocytes. It acts as a tyrosine kinase substrate in lymphoid cells and thus, may function in and be regulated by tyrosine kinase activity. Leupaxin facilitates adhesion and invasion of prostate carcinoma cells. It can form a complex with PYK2 and PTP-PEST in various cells such as monocytes and osteoclasts and in prostate cancer cells. In osteoclasts, leupaxin acts as a key nucleating component of the osteoclast podosomal signaling complex in the adhesion zone.

Physical form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Storage and Stability

Store at –20 °C. For continuous use, the product may be stored at 2–8 °C for up to one month. For extended storage, freeze at –20 °C in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Storage Class Code: 10 - Combustible liquids
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable